National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.

MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.

Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.

The unexpected firing of Arcturus CEO Joseph Payne kicked off a bitter public battle for control of the RNA therapeutics firm after a reverse merger with Alcobra in November. The dispute now settled, the new board has reinstated Payne at Arcturus' helm.